EDIT
Editas Medicine Inc

17,108
Loading...
Loading...
News
all
press releases
Why Is Editas (EDIT) Down 16.9% Since Last Earnings Report?
Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks·5d ago
News Placeholder
More News
News Placeholder
Editas Nominates EDIT-401 as Lead In Vivo Therapy for High Cholesterol
EDIT nominates EDIT-401, a one-time in vivo gene editing therapy, as its lead pipeline candidate to cut the risk of elevated cholesterol.
Zacks·13d ago
News Placeholder
Editas Medicine (EDIT) Reports Q2 Loss, Tops Revenue Estimates
Editas (EDIT) delivered earnings and revenue surprises of -53.66% and +320.94%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Beats Revenue Estimates
TScan Therapeutics (TCRX) delivered earnings and revenue surprises of 0.00% and +58.07%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Humacyte, Inc. (HUMA) Reports Q2 Loss, Misses Revenue Estimates
Humacyte, Inc. (HUMA) delivered earnings and revenue surprises of -60.00% and -73.60%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Are Medical Stocks Lagging Editas Medicine (EDIT) This Year?
Here is how Editas Medicine (EDIT) and Adherex Technologies Inc. (FENC) have performed compared to their sector so far this year.
Zacks·2mo ago
News Placeholder
MiMedx (MDXG) Q2 Earnings and Revenues Beat Estimates
MiMedx (MDXG) delivered earnings and revenue surprises of +66.67% and +10.45%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
3 Genomics Stocks Worth Adding to Your Portfolio in 2025
CRISPR-based innovators like NTLA, EDIT and PRME are gaining traction as genomics reshapes the future of medicine and biotech
Zacks·2mo ago
News Placeholder
Why Is Editas (EDIT) Up 40% Since Last Earnings Report?
Zacks·3mo ago
News Placeholder
EXEL Q1 Earnings Beat, 2025 Sales View Up as Cabometyx Drives Top Line
Zacks·4mo ago

Latest EDIT News

View

Advertisement. Remove ads.

Advertisement. Remove ads.